Wyeth Defends Clinical Trial Standards After Indian Baby’s Death
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Wyeth has defended its "high-quality" clinical patient trial standards after India's drug quality regulator ordered a review of trials for an advanced pneumonia vaccine by the Indian unit of the U.S. pharmaceutical giant following the death of a baby